Abstract
Alzheimer’s disease (AD) is the most common form of dementia characterized by the prevalent memory impairment. Mild cognitive impairment (MCI) may represent the early stage of AD, in particular when MCI patients show biomarkers consistent with AD pathology (MCI due to AD). Neuropsychiatric symptoms (NPS) frequently affect both MCI and AD patients. Cerebrospinal-fluid (CSF) tau and β-amyloid 42 (Aβ 42 ) levels are actually considered the most sensitive and specific biomarkers for AD neurodegeneration. In the present retrospective observational study, we evaluated CSF biomarkers and neuropsychological data (also including NPS measured by the neuropsychiatric inventory—NPI) in a population of patients affected by MCI due to AD compared with mild to moderate AD patients. We documented higher NPI scores in MCI compared with AD patients. In particular, sub-items related to sleep, appetite, irritability, depression, and anxiety were higher in MCI than AD. We also found the significant correlation between NPS and CSF AD biomarkers in the whole population of MCI and AD patients. Consistently, t-tau/Aβ 42 ratio correlated with NPS in all the MCI and AD patients. These results suggest the more prevalent occurrence of NPS in MCI patients showing AD pathology and converting to dementia than AD patients. Moreover, a more significant degree of AD neurodegeneration, featured by high t-tau/Aβ 42 ratio, correlated with more severe NPS, thus supposing that in MCI and AD patients a more extensive AD neurodegeneration is related to more severe behavioral disturbances.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Alzheimer’s disease
- Cognitive impairment
- CSF biomarkers
- Mild cognitive impairment
- Neuropsychiatric symptoms
ASJC Scopus subject areas
- Dermatology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients : a retrospective observational study. / Scaricamazza, Eugenia; Colonna, Isabella; Sancesario, Giulia Maria; Assogna, Francesca; Orfei, Maria Donata; Franchini, Flaminia; Sancesario, Giuseppe; Mercuri, Nicola Biagio; Liguori, Claudio.
In: Neurological Sciences, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients
T2 - a retrospective observational study
AU - Scaricamazza, Eugenia
AU - Colonna, Isabella
AU - Sancesario, Giulia Maria
AU - Assogna, Francesca
AU - Orfei, Maria Donata
AU - Franchini, Flaminia
AU - Sancesario, Giuseppe
AU - Mercuri, Nicola Biagio
AU - Liguori, Claudio
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Alzheimer’s disease (AD) is the most common form of dementia characterized by the prevalent memory impairment. Mild cognitive impairment (MCI) may represent the early stage of AD, in particular when MCI patients show biomarkers consistent with AD pathology (MCI due to AD). Neuropsychiatric symptoms (NPS) frequently affect both MCI and AD patients. Cerebrospinal-fluid (CSF) tau and β-amyloid 42 (Aβ 42 ) levels are actually considered the most sensitive and specific biomarkers for AD neurodegeneration. In the present retrospective observational study, we evaluated CSF biomarkers and neuropsychological data (also including NPS measured by the neuropsychiatric inventory—NPI) in a population of patients affected by MCI due to AD compared with mild to moderate AD patients. We documented higher NPI scores in MCI compared with AD patients. In particular, sub-items related to sleep, appetite, irritability, depression, and anxiety were higher in MCI than AD. We also found the significant correlation between NPS and CSF AD biomarkers in the whole population of MCI and AD patients. Consistently, t-tau/Aβ 42 ratio correlated with NPS in all the MCI and AD patients. These results suggest the more prevalent occurrence of NPS in MCI patients showing AD pathology and converting to dementia than AD patients. Moreover, a more significant degree of AD neurodegeneration, featured by high t-tau/Aβ 42 ratio, correlated with more severe NPS, thus supposing that in MCI and AD patients a more extensive AD neurodegeneration is related to more severe behavioral disturbances.
AB - Alzheimer’s disease (AD) is the most common form of dementia characterized by the prevalent memory impairment. Mild cognitive impairment (MCI) may represent the early stage of AD, in particular when MCI patients show biomarkers consistent with AD pathology (MCI due to AD). Neuropsychiatric symptoms (NPS) frequently affect both MCI and AD patients. Cerebrospinal-fluid (CSF) tau and β-amyloid 42 (Aβ 42 ) levels are actually considered the most sensitive and specific biomarkers for AD neurodegeneration. In the present retrospective observational study, we evaluated CSF biomarkers and neuropsychological data (also including NPS measured by the neuropsychiatric inventory—NPI) in a population of patients affected by MCI due to AD compared with mild to moderate AD patients. We documented higher NPI scores in MCI compared with AD patients. In particular, sub-items related to sleep, appetite, irritability, depression, and anxiety were higher in MCI than AD. We also found the significant correlation between NPS and CSF AD biomarkers in the whole population of MCI and AD patients. Consistently, t-tau/Aβ 42 ratio correlated with NPS in all the MCI and AD patients. These results suggest the more prevalent occurrence of NPS in MCI patients showing AD pathology and converting to dementia than AD patients. Moreover, a more significant degree of AD neurodegeneration, featured by high t-tau/Aβ 42 ratio, correlated with more severe NPS, thus supposing that in MCI and AD patients a more extensive AD neurodegeneration is related to more severe behavioral disturbances.
KW - Alzheimer’s disease
KW - Cognitive impairment
KW - CSF biomarkers
KW - Mild cognitive impairment
KW - Neuropsychiatric symptoms
UR - http://www.scopus.com/inward/record.url?scp=85064050403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064050403&partnerID=8YFLogxK
U2 - 10.1007/s10072-019-03840-4
DO - 10.1007/s10072-019-03840-4
M3 - Article
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
ER -